TCGA and ACRG driven molecular classification identifies biologically distinct gastric cancer subtypes in Iranian patients
Gastric cancer (GC) is a highly heterogeneous disease with diverse molecular and clinical features. Molecular classifications by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) have improved our understanding of GC biology and therapeutic stratification. Yet their clinical utility is limited by high cost and technically complex methods, and no comprehensive studies have been conducted in the Iranian population. In this study, we applied a panel-based approach integrating PCR-based microsatellite instability (MSI) analysis, quantitative real-time PCR for gene expression profiling, and Sanger sequencing for hotspots mutation detection to assess key molecular features, including EBV infection, MSI status, TP53 mutations, and expression of CDH1, VIM, MDM2, and CDKN1A. Statistical analyses were performed using appropriate parametric and nonparametric tests, with p < 0.05 considered statistically significant. Using the TCGA framework, tumors were classified as EBV-positive (7.3%), MSI-H (9.8%) and MSI-L (7.3%), genomically stable (GS, 36.5%), chromosomal instability (CIN, 29.2%), with 9.8% remaining unclassified. Application of the ACRG classification identified MSI-H (9.8%) and MSI-L (7.3%), 19.5% cases as MSS/EMT (CDH1-low, VIM-high), 36.5% as MSS/TP53− (P21-low and/or MDM2-high), and 26.8% as MSS/TP53+. Notably, MDM2 expression showed a significant association with tumor size ( P = 0.0163), and tumor size varied significantly among subtypes defined by the ACRG classification ( P = 0.0152). These findings demonstrate that both TCGA and ACRG classifications, particularly the latter, can be effectively applied to a moderately sized cohort, revealing biologically and clinically distinct GC subtypes. These findings demonstrate the feasibility of applying surrogate TCGA and ACRG molecular classification frameworks in an Iranian gastric cancer cohort and provide a basis for further validation in larger studies.
Authors
- Seyed Mohammad Akrami (ORCID: https://orcid.org/0000-0003-0169-0202)
- Reza Shirkoohi (ORCID: https://orcid.org/0000-0003-1642-0483)
- Amirhossein Razavirad (ORCID: https://orcid.org/0000-0003-0477-8744)
- Àmirnader Emami Razavi (ORCID: https://orcid.org/0000-0001-6811-6075)
- Zeinab Jamali (ORCID: https://orcid.org/0000-0001-6030-1794)
Institutions
- Imam Khomeini Hospital (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s12672-026-06278-1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tehran University of Medical Sciences and Health Services